Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 14 stocks Jim Cramer recently shared insights on. Discussing the ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some ...

Gun-related suicides in the U.S. reached record highs for the third straight year in 2023, a new report on gun violence says.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...